|1.||Wright, William S: 1 article (01/2011)|
|2.||Carter, Patsy R: 1 article (01/2011)|
|3.||Zhang, Songlin: 1 article (01/2011)|
|4.||McElhatten, Robert M: 1 article (01/2011)|
|5.||Harris, Norman R: 1 article (01/2011)|
|6.||Fraig, Mostafa: 1 article (06/2008)|
|7.||Garrett-Mayer, Elizabeth: 1 article (06/2008)|
|8.||Watson, Dennis K: 1 article (06/2008)|
|9.||Ghoneim, Mohamed A: 1 article (06/2008)|
|10.||Moussa, Omar: 1 article (06/2008)|
06/30/1989 - "The inhibitory action of GR32191 on platelet aggregation, mural thrombus formation and platelet protein storage granule secretion suggests that it has potential in treating thrombotic disease in man."
06/01/1997 - "Vapiprost inhibited arterial thrombus formation in all dogs, but thrombus formation returned with the addition of epinephrine. "
10/05/1992 - "Vapiprost prolonged the time required to occlude the artery with thrombus and inhibited collagen-induced rat platelet aggregation in whole blood ex vivo, in a dose-dependent manner. "
10/05/1992 - "Comparison of the inhibitory effects of the TXA2 receptor antagonist, vapiprost, and other antiplatelet drugs on arterial thrombosis in rats: possible role of TXA2."
07/01/1992 - "3. The thrombolytic effects of tissue-type plasminogen activator (tPA) on the established arterial thrombus in the presence and absence of vapiprost were also studied in the same model. "
|2.||Asthma (Bronchial Asthma)
09/01/1992 - "The effect of GR32191 (a thromboxane receptor antagonist) on airway responsiveness in asthma."
03/01/1991 - "Effect of GR32191, a potent thromboxane receptor antagonist, on exercise induced bronchoconstriction in asthma."
01/01/1991 - "The evidence for the involvement of these TP-receptors in human asthma is equivocal; however, the recent development of potent, selective TP-receptor blocking drugs such as GR32191 has provided the opportunity to answer this question. "
01/01/1991 - "GR32191 and the role of thromboxane A2 in asthma--preclinical and clinical findings."
|3.||Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
03/01/1995 - "Inhibitory effect of clopidogrel, vapiprost and argatroban on the middle cerebral artery thrombosis in the rat."
07/01/1993 - "We aimed to evaluate a modified tissue-type plasminogen activator, SUN9216, and the combination of SUN9216 and a thromboxane A2 receptor antagonist, vapiprost, in a rat middle cerebral artery thrombosis model. "
07/01/1993 - "Evaluation of the combination of a tissue-type plasminogen activator, SUN9216, and a thromboxane A2 receptor antagonist, vapiprost, in a rat middle cerebral artery thrombosis model."
04/01/1992 - "In GR32191 treated MRL-lpr/lpr mice, renal hemodynamic function and proteinuria were not significantly different from congenic MRL-+/+ controls. "
04/01/1992 - "Administration of GR32191 also reduced proteinuria from 18.1 +/- 11.6 to 3.7 +/- 1.3 mg/24 hours (P less than 0.05). "
03/01/1990 - "In Group 3 rats GR 32191 failed to influence progressive proteinuria and severity of glomerulosclerosis which were comparable to those in Group 1. Bleeding time was not prolonged, and in vitro platelet aggregation was inhibited only when AA was used as aggregating agent. "
11/01/1992 - "NE 3 x 10(-5) mol/l-induced contractures of mesenteric and femoral arterial preparations were not influenced by any concentrations of vapiprost. "
07/01/1994 - "2. A bolus administration of U46619 or PGF2 alpha produced sustained contracture of these preparations, which was concentration-dependently relaxed by cumulative vapiprost. "
|3.||Thromboxane Receptors (Thromboxane Receptor)
|4.||Thromboxane A2 (A2, Thromboxane)
|5.||Tissue Plasminogen Activator (Alteplase)
|6.||Prostaglandin H2 Thromboxane A2 Receptors
|7.||15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
|10.||GTP-Binding Protein alpha Subunits